New Study: Hormone Therapy and Weight Loss Benefits for Postmenopausal Women
A recent study has highlighted a promising approach for women experiencing weight gain after menopause. Research from the Mayo Clinic suggests that combining hormone therapy with an obesity drug may result in more significant weight loss.
The study found that postmenopausal women using both hormone therapy and tirzepatide, a drug approved by the FDA to treat obesity, managed to lose around 35% more weight than those who only took tirzepatide. The findings were published in a recent issue of The Lancet Obstetrics, Gynaecology, & Women’s Health.
Dr. Regina Castaneda, the lead author, expressed that this study offers valuable insights for creating better strategies to manage health risks in postmenopausal women, particularly as hormonal changes can lead to obesity and other health issues like heart disease and Type 2 diabetes.
Researchers tracked 120 postmenopausal women who were overweight or obese. Out of these, 40 women were on hormone therapy while 80 received only the tirzepatide. Those on hormone therapy experienced an average weight loss of 19.2%, compared to 14.0% in the others.
While the results are exciting, researchers noted that the study is observational, meaning it’s challenging to conclude that hormone therapy directly caused greater weight loss. Dr. Maria Daniela Hurtado Andrade, the study’s senior author, mentioned that the women taking hormone therapy might have also benefited from improved sleep and well-being, which helps in sticking to a healthy diet and exercise routine.
Experts in the field have advised caution when interpreting the results. Dr. Gillian Goddard, a board-certified endocrinologist, pointed out that the differences observed could be due to many factors, such as the general health of the participants. Healthier women might make better lifestyle choices, contributing to their weight loss success.
Despite these uncertainties, the study opens new doors for further research. Experts agree that the combination of tirzepatide and hormone therapy appears safe for most women, although hormone therapy isn’t suitable for everyone, especially those with certain health concerns.
Moving forward, researchers aim to conduct more rigorous trials to confirm these findings and explore their potential benefits in improving overall health for postmenopausal women. If the results prove consistent, they could lead to effective strategies for managing weight and reducing health risks for millions of women during this stage of life.
